Multiple Portfolio Companies of Xingze Capital Honored in Qingke's 2024 VENTURE50 List

This year's selection continues with the dual lists of the "Fengyun榜" (Fengyun Ranking) and the "Xinyabang" (New Bud Ranking) 50, as well as the four major mainstream industry rankings: Hard Technology, Artificial Intelligence, Healthcare, and New Energy & Materials. The "Fengyun Ranking" evaluates companies that are either in the post-B round financing stage or were established before 2021 and remain unlisted. The "New Bud Ranking" evaluates companies that are in the B-round or earlier financing stage and were established after 2021 and remain unlisted.

About VENTURE50

VENTURE50 Investment Value Enterprises (Abbreviated as V50), founded by Zero2IPO Group (1945.HK) in 2006, has undergone nineteen years of development and refinement to become a benchmark for investment in high-growth enterprises in China. As of December 2024, the event has seen over 79,000 participating companies, assisting selected enterprises in raising more than 312.325 billion RMB, with a subsequent financing rate of 57.02% and an IPO rate of 10.23%.

VENTURE50 2024, based on enterprises' different development stages and industry distributions, establishes the Prestige List, New Bud List, and Industry List. It gathers thousands of technology innovation enterprises and invites hundreds of top-tier investment institutions for evaluation. Through multiple rounds of "online selection + offline engagement," it builds an efficient interactive platform for technology enterprises and investment institutions, actively promoting the integration of industry and capital. It also accelerates enterprise implementation, advances the construction of a modern industrial system, and fully supports high-quality development in technological innovation.

Evopoint Biosciences, established in 2017, is a platform-based innovative drug company with both strong research capabilities and commercialization capacity. Based on three self-developed technology platforms—targeted therapy, anti-infectives, and PROTAC—Evopoint Biosciences has developed an innovative drug pipeline that includes BLI inhibitors, EZH2 inhibitors, hURAT1 inhibitors, and next-generation ADCs, covering disease areas such as oncology, anti-infectives, and metabolism. Currently, the company has multiple products in clinical development stages. Relying on excellent product data and out-licensing capabilities, Evopoint Biosciences has reached several out-licensing collaborations with well-known companies both domestically and internationally, with a total value of billions of US dollars. Since its founding, Evopoint Biosciences has always been committed to benefiting human health, focusing on providing high-quality solutions for significant unmet clinical needs worldwide.

Bio-Link is a high-tech enterprise group that provides process solutions for the life sciences sector, focusing on the research, development, and manufacturing of critical process equipment and consumables for vaccines, antibody drugs, cell therapy, gene therapy, and other biopharmaceuticals.

Argo Biopharma was founded in 2021 as a clinical-stage biotechnology company dedicated to developing a new generation of siRNA drugs to provide better treatment options for patients worldwide. Over the past three years, Argo Biopharma has built a rich and differentiated pipeline of siRNA drug candidates covering a wide range of indications, including cardiovascular diseases, rare diseases, central nervous system (CNS) disorders, viral infections, and metabolic diseases. Currently, five siRNA drugs from Argo Biopharma have entered clinical trial stages. Notably, in January 2024, Argo Biopharma reached licensing and strategic collaboration agreements with Novartis for multiple RNAi projects. Under the agreement, Argo Biopharma will receive an upfront payment of $185 million from Novartis, along with milestone payments and tiered royalties on commercial sales, bringing the total potential transaction value to nearly $4.2 billion.